For megaloblastic anemia, the cause matters
Disclosure of interest: Nothing to disclose E-Posters - RISK FACTORS - PRIMARY AND SECONDAR PREVENTION 05.00 - RISK FACTORS AND PREVENTION (PRIMARY AND SECONDARY) - 05.01 - PREVENTION P2471 - ESOC25-388 COMPARARIVE EFFECTIVENESS AND SAFETY OF DIRECT ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION PATIENTS WITH DEMENTIA Sheng-Feng Sung 1 , Cheng-Yang Hsieh 2 , Hsin-Yi Yang 3 , Chen-Wen Fang 4,5 1 Division of Neurology, Department of Internal Medicine, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan, 2 Department of Neurology, Tainan Sin Lau Hospital, Tainan City, Taiwan, 3 Clinical Data Center, Department of Medical Research, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chiayi City, Taiwan, 4 Department of Neurology, National Taiwan University Hospital, Yunlin branch, Douliu City, Taiwan, 5 Department of Biomedical Engineering, National Cheng Kung University., Tainan City, Taiwan Background and Aims: Stroke or systemic embolism is the most severe complication of atrial fibrillation (AF)
This formulation is manufactured to high purity standards and supplied as an LPS-free peptide and endotoxin-free peptide , ensuring suitability for sensitive research applications
BPC-157 10mg is intended exclusively for laboratory, educational, and scientific research applications
Cytoprotection and Organoprotection (Robert's Concept, Epithelial and Endothelial Integrity, Protection Against Noxious Agents) A foundational concept in understanding BPC-157's broad therapeutic scope is "cytoprotection," originally defined by Robert
